| |
Tuesday, January 23, 2024 | 11am ET / 8am PT Join a cutting-edge conversation on January 23, 2024 with Real Chemistry and Quid as they explore how their partnership has forged a deeper understanding of patient insights. Register now.
|
|
Today’s Big NewsJan 5, 2024 |
| By Max Bayer Intellia Therapeutics is the latest gene editing biotech to downsize following a dismal year for the industry. |
|
|
|
By Zoey Becker Both companies opted not to renew their 2024 memberships with the Biotechnology Innovation Organization (BIO). UCB will still retain its membership in other top trade groups, including the Pharmaceutical Research and Manufacturers Association of America (PhRMA). |
By Annalee Armstrong Less than a month after AlloVir suffered a triple phase 3 failure, the allogeneic T cell immunotherapy biotech is cutting 95% of its workforce. |
By Conor Hale The CE mark covers the Micra AV2 and VR2 cardiac implants, which the medtech giant describes as the world’s smallest. |
|
Wednesday, January 24, 2024 | 2pm ET / 11am PT Join industry experts to hear how digital collection of patient-reported outcomes (PROs) can lay the foundation for advancing health equity, which methods can ensure that PROs are relevant for diverse populations, and what challenges and opportunities still lie ahead. Register now.
|
|
By Kevin Dunleavy Three days after the FDA included Novo Nordisk’s semaglutide treatments Ozempic and Wegovy on a list of medicines that it would monitor for side effects—one of them suicide ideation—a study of medical records of patients shows no link between use of the GLP-1 drugs and an increase in suicidal thoughts. In fact, the research shows that those who were on semaglutide were less likely to have suicidal thoughts than patients on other diabetes and obesity meds. |
By Annalee Armstrong Apparently thrice is nice for Boehringer Ingelheim, which has now announced a trio of deals this week. Friday’s tie-up involves €410 million ($449 million) for Kyowa Kirin to work on fibro-inflammatory diseases. |
By Ben Adams The attempted merger between leading biopharma data provider IQVIA and pharma ad specialist DeepIntent has been put on ice after continued scrutiny from the U.S. government. |
By Zoey Becker The Petaluma, CA facility produced disposable plastics and expanded in 2020 to keep up with COVID testing demands. Now, the site will shut down in July. |
By Conor Hale The FDA has handed down a Class I recall label, the agency’s most serious, to a now-corrected software issue that could have resulted in delivering ten times the desired insulin dose from Insulet’s Omnipod 5 automated pump. |
By Nick Paul Taylor Nobody can accuse Allogene Therapeutics of lacking confidence. Believing that its CAR-T can boost cure rates, and thereby potentially make later-line treatment “obsolete,” the biotech has stopped two trials in advanced lymphoma patients to focus on a new study in people with minimal residual disease (MRD). |
By Fraiser Kansteiner In the phase 4 study, Theravance and Viatris’ Yupelri failed to demonstrate greater lung function improvement in adults with COPD versus Spiriva delivered by a dry powder inhaler, Theravance said Friday. |
By Gabrielle Masson CureVac says its monovalent and bivalent COVID-19 vaccine candidates produced meaningful immune responses at lower doses than similar approved vaccines and were generally safe—though grade 3 adverse events were recorded in the mid-stage trial. |
Fierce podcastsDon’t miss an episode |
| | This week on "The Top Line," Fierce Biotech staff writer Gabrielle Masson and senior editor Annalee Armstrong look back at the year in biotech, which was defined by massive layoffs across the industry. They also discuss their favorite stories of the year, including an appearance from a popstar whose reputation precedes her. |
|
|---|
|
|
|
This resource describes some key factors worth considering as you think through how to construct an effective and robust screening cascade. We will focus initially on the hit-to-lead phase, as this encompasses the types of assays required and highlights some general considerations. Download now.
|
|
| WhitepaperThe road to digital health innovation is exciting but complex and requires thoughtful navigation; this whitepaper serves as your guide through this process. Sponsored by: S3 Connected Health |
| WhitepaperDiscover how to effectively classify highly potent APIs and the steps required to develop containment protocols and manufacturing processes that are both safe and efficient. Catalent |
| eBook This e-book explores 7 factors that are critical to the success of emerging biopharma companies, whether they plan to out-license, partner, or launch & commercialize products. It’s an essential resource for emerging companies with products in all stages of development.
Presented by Blue Matter, strategic consultants in the life sciences |
| WhitepaperqPCR Assay Design - Quantify microbial biomarkers with high sensitivity and dynamic range Sponsored by: Diversigen |
| WhitepaperStreamline your clinical cell therapy with our GMP-compliant ribonucleoprotein (RNP) manufacturing as you scale up without compromising on quality to tackle complex regulatory requirements. Sponsored by: Aldevron |
| Whitepaper High performance computing (HPC) combined with artificial intelligence (AI) and machine learning (ML) can speed up research and development processes and dramatically reduce reliance on expensive clinical trials. Download the free solution brief to learn more. Sponsored By: AWS, NVIDIA, and Rescale |
| Whitepaper Improving efficiency and productivity in biologics manufacturing is a longstanding goal within today’s industry, especially now as new and increasingly complex molecules are fundamentally changing technological and operational approaches to drug development. Process intensification can help accelerate this pace of innovation through advanced process development techniques and high productivity manufacturing platforms. Sponsored by: Lonza |
| Whitepaper As a leader of technology transfer activities in the industry, Lonza understands the challenges associated with this critical step. Download this White Paper today to learn more. Sponsored by: Lonza |
| |
|
